Rhea-AI Summary
NantKwest (NASDAQ: NK) and CBR by Generate Life Sciences announced a collaboration to develop a COVID-19 treatment using newborn stem cells. CBR will supply umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for their manufacturing process. This strategic alliance is expected to expedite the development of a new cellular therapy to address complications from COVID-19, with patient trials starting in Fall 2020 and potential market availability by early 2021. NantKwest's IND application for MSCs has already received FDA authorization, highlighting its commitment to innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags